Various Radiopharmaceuticals

The Department of the Army Medical Command has issued a Special Notice regarding various radiopharmaceuticals through their Medical Readiness Contracting Office-West. This notice announces the Army's intent to award a sole source contract to Medi-Physics Inc. for FDA-approved radiopharmaceuticals including In-111 Oxine, Ceretec stabilized kit with cobalt (5 vials), I-123 DatScan, and In-111 DTPA. The contract will be structured as a firm fixed-price call order covering the period from October 1, 2025 through September 30, 2026. The anticipated award date is on or about September 15, 2025, with responses to this notice due by July 25, 2025. The procurement falls under NAICS code 325412 (Pharmaceutical Preparation Manufacturing) with a size standard of 1,300 employees.

The Army is utilizing the sole source procurement authority under 10 United States Code 3204(a)(1), asserting that only one responsible source can satisfy the agency's requirements for these specialized radiopharmaceuticals. The notice explicitly states that this is not a request for competitive proposals and that no capability briefings or telephonic inquiries will be honored by the contracting office. While the government retains discretion to potentially compete this contract based on any responses received, the current intent is to proceed with the sole source award to Medi-Physics Inc. Contractors interested in this opportunity should note that any response must demonstrate their ability to meet the Army's specific radiopharmaceutical requirements, though the notice emphasizes the government's position that only the incumbent contractor can fulfill these needs. The procurement supports the Army's medical readiness mission by ensuring access to critical radiopharmaceutical supplies for diagnostic and therapeutic purposes.